[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center.  Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Success Stories

Laser Capture Microdissection (LCM)

NIH’s (NCI & NICHD) Contribution

  • Conceived the idea of microdissection
  • Invented a special thermoplastic polymer film activated by laser beams
  • Developed a prototype LCM unit that used a carbon dioxide laser

Arcturus’ Contribution

  • Contributed the laser diode technology
  • Developed a prototype Laser Diode System LCM

Results of Collaboration

  • Product – Laser Capture Microdissection machine
  • More than 700 articles have been published based on LCM technology
  • Nearly a thousand LCM machines have been sold for use in research on breast, prostate, and pancreatic cancers

Multi-Replica Blotting Kit

NIH’s (NCI) Contribution

  • Developed Layered Expression Scanning (LES) technology

20/20 GeneSystems’ Contribution

  • Refined the LES system in collaboration with the NCI, NIH
  • Commercialized the Multi-Replica Blotting Kit

Results of Collaboration

  • Product – Multi-Replica Blotting Kit
  • The kit allows the simultaneous detection of up to ten different proteins of interest from one protein gel using Western Blot technique


NIH’s (NCI) Contribution

  • Conducted preclinical studies for Velcade®
  • Developed a formulation with a longer, stable shelf life

Industrial Partners’ Contribution

  • Myogenetics synthesized the active ingredient for Velcade®
  • ProScript conducted preclinical oncology studies in collaboration with institutions including the NCI, NIH
  • Millennium Pharmaceuticals initiated the clinical trials that resulted in FDA approval

Results of Collaboration

  • Product – Anti-cancer drug Velcade®
  • FDA approved Velcade® as treatment for refractory multiple myeloma, which accounts for 2% of all cancer deaths each year
  • Velcade® is being clinically tested against ovarian, colon, pancreatic, lung, and prostate cancers, as well as leukemia and non-Hodgkin’s lymphoma


NIH’s (NCI) Contribution

  • Identified paclitaxel from the Pacific yew tree bark by screening natural products for antitumor activity
  • Conducted pre-clinical testing and clinical trials
  • Developed alternative drug administration methods

Bristol-Myers Squibb’s Contribution

  • Developed supplies of Taxol® by licensing Taxol semisynthesis technology from Florida State University
  • Collaborated in the clinical development with the NIH

Results of Collaboration

  • Product - Anti-cancer drug Taxol®
  • FDA approved Taxol® for the treatment of breast, ovarian, lung cancer and Kaposi’s sarcoma
  • Over 1 million patients received treatment with Taxol® (paclitaxel)

Paclitaxel-Eluting Coronary Stent System

NIH’s (NIA) Contribution

  • Invented the method of using the anticancer drug paclitaxel at a lower dosage to treat restenosis
  • Incorporated the drug in a slow-release polymer for coated stent
  • Carried out the early animal experiments

Industrial Partners’ Contribution

  • Invented the method of using stent coated with paclitaxel for clinical applications
  • Angiotech collaborated with Boston Scientific to develop the coated stent for human use
  • Boston Scientific launched the commercial product

Results of Collaboration

  • Product - Taxus® Express2TM device
  • This product and similar drug-coated stents are expected to substantially replace open-heart bypass surgeries currently performed on more than 350,000 Americans a year
Page Last Updated: 12-02-2008